TY - CHAP
T1 - Neuroprotective effects of a potent bradykinin B2 receptor antagonist HOE-140 on microvascular permeability, blood flow disturbances, edema formation, cell injury and nitric oxide synthase upregulation following trauma to the spinal cord
AU - Sharma, Hari Shanker
AU - Feng, Lianyuan
AU - Muresanu, Dafin Fior
AU - Castellani, Rudy J.
AU - Sharma, Aruna
N1 - Funding Information:
Supported by grants from the Swedish Medical Research Council (Nr 2710-HSS), Göran Gustafsson Foundation, Stockholm, Sweden (HSS), Astra Zeneca, Mölndal, Sweden (H.S.S./A.S.), the National Institutes of Health (R01 AG028679); The University Grants Commission, New Delhi, India (H.S.S./A.S.), Ministry of Science & Technology, People Republic of China; Ministry of Science & Technology, Govt. of India (H.S.S./A.S.), Indian Medical Research Council, New Delhi, India (H.S.S./A.S.) and India-EU Co-operation Program (A.S./H.S.S.) & Society for Neuroprotection and Neuroplasticity (SSNN), Romania. We thank Suraj Sharma, Uppsala, Sweden for computer and graphic support.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019
Y1 - 2019
N2 - Bradykinin is a mediator of vasogenic brain edema formation. Recent reports suggest that bradykinin interacts with nitric oxide synthase (NOS) system in the central nervous system (CNS). However, role of bradykinin in spinal cord injury (SCI) induced alterations in the blood-spinal cord barrier (BSCB), spinal cord blood flow (SCBF), edema formation and cell changes are still not well known. Our previous reports showed that SCI induces marked upregulation of neuronal NOS (nNOS) in the cord associated with BSCB disruption, edema formation and cell injury. Thus, a possibility exists that bradykinin participates in SCI induced nNOS upregulation and cord pathology. To explore this idea a potent bradykinin B2 receptor antagonist HOE-140 was used in our rat model of SCI and cord pathology. SCI was inflicted in Equithesin anesthetized rats by making a longitudinal incision (2 mm deep and 5 mm long) into the right dorsal horn of the T10-11 segment. The animals were allowed to survive 5 h after injury. A focal SCI significantly disrupted BSCB to Evans blue and [131]I-sodium in the traumatized and adjacent segments. Interestingly, far remote spinal cord segments C4 and T5 segments also affected within 5 h. These spinal cord segments also exhibited pronounced reductions in the SCBF (mean—30%), increased edematous swelling and profound neuronal damages. Upregulation of nNOS expression is seen in both the dorsal and ventral horns of the spinal cord exhibiting cord pathology. At the ultrastructural level, exudation of lanthanum is seen within the endothelial cell cytoplasm and occasionally in the basal lamina. Pretreatment with low doses of HOE-140 (0. 1 mg to 1 mg/kg, i.v.) 30 min prior to SCI significantly enhanced the SCBF and reduced the BSCB disruption, edema formation, nNOS upregulation and cell injury. However, HOE-140 in doses ranging from 2 mg to 5 mg/kg, i.v. did not induce significant neuroprotection. These observations are the first to suggest that bradykinin B2 receptors play an important role in BSCB permeability, SCBF, edema formation, nNOS upregulation and cell injury following acute SCI, not reported earlier.
AB - Bradykinin is a mediator of vasogenic brain edema formation. Recent reports suggest that bradykinin interacts with nitric oxide synthase (NOS) system in the central nervous system (CNS). However, role of bradykinin in spinal cord injury (SCI) induced alterations in the blood-spinal cord barrier (BSCB), spinal cord blood flow (SCBF), edema formation and cell changes are still not well known. Our previous reports showed that SCI induces marked upregulation of neuronal NOS (nNOS) in the cord associated with BSCB disruption, edema formation and cell injury. Thus, a possibility exists that bradykinin participates in SCI induced nNOS upregulation and cord pathology. To explore this idea a potent bradykinin B2 receptor antagonist HOE-140 was used in our rat model of SCI and cord pathology. SCI was inflicted in Equithesin anesthetized rats by making a longitudinal incision (2 mm deep and 5 mm long) into the right dorsal horn of the T10-11 segment. The animals were allowed to survive 5 h after injury. A focal SCI significantly disrupted BSCB to Evans blue and [131]I-sodium in the traumatized and adjacent segments. Interestingly, far remote spinal cord segments C4 and T5 segments also affected within 5 h. These spinal cord segments also exhibited pronounced reductions in the SCBF (mean—30%), increased edematous swelling and profound neuronal damages. Upregulation of nNOS expression is seen in both the dorsal and ventral horns of the spinal cord exhibiting cord pathology. At the ultrastructural level, exudation of lanthanum is seen within the endothelial cell cytoplasm and occasionally in the basal lamina. Pretreatment with low doses of HOE-140 (0. 1 mg to 1 mg/kg, i.v.) 30 min prior to SCI significantly enhanced the SCBF and reduced the BSCB disruption, edema formation, nNOS upregulation and cell injury. However, HOE-140 in doses ranging from 2 mg to 5 mg/kg, i.v. did not induce significant neuroprotection. These observations are the first to suggest that bradykinin B2 receptors play an important role in BSCB permeability, SCBF, edema formation, nNOS upregulation and cell injury following acute SCI, not reported earlier.
KW - B2 receptor
KW - Blood-spinal cord barrier
KW - Bradykinin
KW - Cell injury
KW - Edema formation
KW - Evans blue
KW - HOE-140
KW - I-sodium
KW - Lanthanum
KW - Neuronal nitric oxide synthase
KW - Spinal cord blood flow
KW - Ultrastructure
UR - http://www.scopus.com/inward/record.url?scp=85068473183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068473183&partnerID=8YFLogxK
U2 - 10.1016/bs.irn.2019.06.008
DO - 10.1016/bs.irn.2019.06.008
M3 - Chapter
C2 - 31349925
AN - SCOPUS:85068473183
SN - 9780128167540
T3 - International Review of Neurobiology
SP - 103
EP - 152
BT - New Therapeutic Strategies for Brain Edema and Cell Injury
A2 - Sharma, Hari Shanker
A2 - Sharma, Aruna
PB - Academic Press Inc
ER -